CANCER Research UK has announced plans to fund a £1.47million research programme set to lead to major advances in lung cancer treatments – the North West’s most common cancer.

A team of scientists led by Dr James O’Connor, from Hale and based at the University of Manchester, will use the cash injection to look at how imaging techniques can be used to improve treatment plans for lung cancer patients.

The Manchester team will work to develop new ways to use imaging techniques like magnetic resonance imaging (MRI) to better understand how lung cancer tumours respond to treatment.

The information they gather could then be used to evaluate new therapies and in the future, might help doctors select the right treatment for each patient.

Every year around 46,400 people are diagnosed with lung cancer in the UK.

Every year in Trafford, around 190 people are diagnosed with lung cancer and around 130 people die from it.

Dr O’Connor, who grew up in Altrincham, said: “We hope this research will transform the way we use scans to monitor how patients respond to new therapies.

“It’s an exciting area where we are aiming to combine drugs that harness the body’s immune system with well-established treatments like radiotherapy, and at the same time, create tests to identify which patients would benefit from these drugs.

“It builds on earlier research but we will be applying it to lung cancer specifically.”

The research will be done in laboratories, with the hope of running clinical trials with patients to test these techniques within three to four years.

Dr O’Connor is one of only two scientists in the country this year to win the Cancer Research UK Advanced Clinician Scientist Fellowship award – aimed at supporting clinicians working in areas spanning basic and translational research.

Karen Noble, Cancer Research UK’s Head of Research Funding, said: “These awards are aimed at helping create the next generation of leaders in cancer research.

“They help encourage clinicians to continue to undertake vital research in conjunction with their clinical work treating patients.

“We hope Dr O’Connor’s important work in Manchester will improve lung cancer treatments for patients not just in Manchester but across the UK in future.”